Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 20Thoracic 12Genitourinary 12Breast 10Tumor-Agnostic 7Lymphoid 7Other hematologic neoplasm 4Gynecologic 4Dermatologic 4CNS 4Other 2Myeloid 2Classical hematology 2Sarcoma 1Plasma cell 1Head & Neck 1

Conditions

Multiple Myeloma 1Dyspnea 1Cardiotoxicity 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Tests × Plasma cell × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡